MR/MMR Vaccine in Measles Control: A Case of Missed Opportunity?
作者信息
Sharma Karun D, Rana Manish K
机构信息
Department of Community Medicine, Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, Andhra Pradesh, India.
Department of Community Medicine, Gujrat Medical Education and Research Society Medical College, Sola, Ahmedabad, Gujarat, India E-mail:
出版信息
Indian J Community Med. 2014 Jan;39(1):49-50. doi: 10.4103/0970-0218.126361.
Abstract
摘要
相似文献
1
MR/MMR Vaccine in Measles Control: A Case of Missed Opportunity?
Indian J Community Med. 2014 Jan;39(1):49-50. doi: 10.4103/0970-0218.126361.
2
[Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
Zhonghua Yu Fang Yi Xue Za Zhi. 2017 Apr 6;51(4):336-340. doi: 10.3760/cma.j.issn.0253-9624.2017.04.011.
3
Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12-13, 2000.
Pediatrics. 2001 May;107(5):E84. doi: 10.1542/peds.107.5.e84.
4
The impact of maternal measles-rubella immunization on the 12-month-old infant's immune response to measles-mumps-rubella vaccine immunogenicity.
Eur J Clin Microbiol Infect Dis. 2009 Jul;28(7):845-7. doi: 10.1007/s10096-009-0702-z. Epub 2009 Feb 20.
5
Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance.
Vaccine. 2002 Jan 15;20(7-8):1134-40. doi: 10.1016/s0264-410x(01)00435-2.
6
Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
Vaccine. 2013 May 31;31(24):2661-6. doi: 10.1016/j.vaccine.2013.04.014. Epub 2013 Apr 17.
7
Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial.
Hum Vaccin Immunother. 2019;15(5):1139-1144. doi: 10.1080/21645515.2019.1578591. Epub 2019 Apr 22.
8
Two doses of measles mumps rubella (MMR) vaccine.
Acta Paediatr Jpn. 1989 Dec;31(6):690-7. doi: 10.1111/j.1442-200x.1989.tb01381.x.
9
Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
Vaccine. 2001 Aug 14;19(31):4473-8. doi: 10.1016/s0264-410x(01)00207-9.
10
Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.
Vaccine. 2021 May 6;39(19):2643-2651. doi: 10.1016/j.vaccine.2021.03.085. Epub 2021 Apr 12.
本文引用的文献
1
Seroprevalence of rubella and immunogenicity following rubella vaccination in adolescent girls in India.
J Infect Dev Ctries. 2011 Dec 13;5(12):874-81. doi: 10.3855/jidc.1847.
2
Congenital rubella syndrome and rubella in Vellore, South India.
Epidemiol Infect. 2011 Jun;139(6):962-6. doi: 10.1017/S0950268810001755. Epub 2010 Jul 20.
3
Sero-Surveillance to Assess Immunity to Rubella and Assessment of Immunogenicity and Safety of a Single dose of Rubella Vaccine in School Girls.
Indian J Community Med. 2010 Jan;35(1):134-7. doi: 10.4103/0970-0218.62575.
4
Laboratory confirmation of congenital rubella syndrome in infants: an eye hospital based investigation.
J Med Virol. 2008 Mar;80(3):536-46. doi: 10.1002/jmv.21097.
5
Prevalence of eye signs in congenital rubella syndrome in South India: a role for population screening.
Br J Ophthalmol. 2007 Nov;91(11):1467-70. doi: 10.1136/bjo.2007.114629.
6
The seroepidemiology of Rubella in Amritsar (Punjab).
Indian J Med Microbiol. 2004 Jan-Mar;22(1):61-3.
7
Rubella prevalence and its transmission in children.
Indian J Pathol Microbiol. 2006 Jan;49(1):54-6.
Zotero 插件